Diffuse large B cell lymphoma natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 2: | Line 2: | ||
{{Diffuse large B cell lymphoma}} | {{Diffuse large B cell lymphoma}} | ||
==Overview== | ==Overview== | ||
Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis.However, the usual treatment for each of these is [[chemotherapy]], often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with | Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis.However, the usual treatment for each of these is [[chemotherapy]], often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with Diffuse large B cell lymphoma can be cured,<ref name="Akyurek2011">{{cite journal |doi=10.1002/cncr.27396 |pmid=22213394 |title=Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab |journal=Cancer |volume=118 |issue=17 |pages=4173–83 |year=2012 |last1=Akyurek |first1=Nalan |last2=Uner |first2=Aysegul |last3=Benekli |first3=Mustafa |last4=Barista |first4=Ibrahim }}</ref> and overall survival for older adults at five years is around 58%.<ref name="Feugier2005">{{cite journal |doi=10.1200/JCO.2005.09.131 |pmid=15867204 |title=Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte |journal=Journal of Clinical Oncology |volume=23 |issue=18 |pages=4117–26 |year=2005 |last1=Feugier |first1=P. |last2=Van Hoof |first2=A |last3=Sebban |first3=C |last4=Solal-Celigny |first4=P |last5=Bouabdallah |first5=R |last6=Fermé |first6=C |last7=Christian |first7=B |last8=Lepage |first8=E |last9=Tilly |first9=H |last10=Morschhauser |first10=F |last11=Gaulard |first11=P |last12=Salles |first12=G |last13=Bosly |first13=A |last14=Gisselbrecht |first14=C |last15=Reyes |first15=F |last16=Coiffier |first16=B }}</ref> | ||
==Prognosis== | ==Prognosis== | ||
Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis. However, the usual treatment for each of these is [[chemotherapy]], often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with | Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis. However, the usual treatment for each of these is [[chemotherapy]], often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with Diffuse large B cell lymphoma can be cured,<ref name="Akyurek2011">{{cite journal |doi=10.1002/cncr.27396 |pmid=22213394 |title=Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab |journal=Cancer |volume=118 |issue=17 |pages=4173–83 |year=2012 |last1=Akyurek |first1=Nalan |last2=Uner |first2=Aysegul |last3=Benekli |first3=Mustafa |last4=Barista |first4=Ibrahim }}</ref> and overall survival for older adults at five years is around 58%.<ref name="Feugier2005">{{cite journal |doi=10.1200/JCO.2005.09.131 |pmid=15867204 |title=Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte |journal=Journal of Clinical Oncology |volume=23 |issue=18 |pages=4117–26 |year=2005 |last1=Feugier |first1=P. |last2=Van Hoof |first2=A |last3=Sebban |first3=C |last4=Solal-Celigny |first4=P |last5=Bouabdallah |first5=R |last6=Fermé |first6=C |last7=Christian |first7=B |last8=Lepage |first8=E |last9=Tilly |first9=H |last10=Morschhauser |first10=F |last11=Gaulard |first11=P |last12=Salles |first12=G |last13=Bosly |first13=A |last14=Gisselbrecht |first14=C |last15=Reyes |first15=F |last16=Coiffier |first16=B }}</ref> | ||
Revision as of 21:17, 20 August 2015
Diffuse large B cell lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Diffuse large B cell lymphoma natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Diffuse large B cell lymphoma natural history, complications and prognosis |
FDA on Diffuse large B cell lymphoma natural history, complications and prognosis |
CDC on Diffuse large B cell lymphoma natural history, complications and prognosis |
Diffuse large B cell lymphoma natural history, complications and prognosis in the news |
Blogs on Diffuse large B cell lymphoma natural history, complications and prognosis |
Directions to Hospitals Treating Diffuse large B cell lymphoma |
Overview
Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis.However, the usual treatment for each of these is chemotherapy, often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with Diffuse large B cell lymphoma can be cured,[1] and overall survival for older adults at five years is around 58%.[2]
Prognosis
Several subtypes of Diffuse large B cell lymphoma have been identified, each having a different clinical presentation and prognosis. However, the usual treatment for each of these is chemotherapy, often in combination with an antibody targeted at the tumour cells. Through these treatments, more than half of patients with Diffuse large B cell lymphoma can be cured,[1] and overall survival for older adults at five years is around 58%.[2]
References
- ↑ 1.0 1.1 Akyurek, Nalan; Uner, Aysegul; Benekli, Mustafa; Barista, Ibrahim (2012). "Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab". Cancer. 118 (17): 4173–83. doi:10.1002/cncr.27396. PMID 22213394.
- ↑ 2.0 2.1 Feugier, P.; Van Hoof, A; Sebban, C; Solal-Celigny, P; Bouabdallah, R; Fermé, C; Christian, B; Lepage, E; Tilly, H; Morschhauser, F; Gaulard, P; Salles, G; Bosly, A; Gisselbrecht, C; Reyes, F; Coiffier, B (2005). "Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte". Journal of Clinical Oncology. 23 (18): 4117–26. doi:10.1200/JCO.2005.09.131. PMID 15867204.